AstraZeneca

AZN: 7,353.50 +105.50 (+1.46%) delayed: 18 Nov 2019, 15:50

Trade now

AstraZeneca Fundamentals

Share Price Information

Name AstraZeneca
Epic AZN
Sector Pharmaceuticals
ISIN GB0009895292
Activites AstraZeneca plc is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Index FTSE 100

Key numbers

Latest Share price (p) 7,353.50 Net gearing (%) 68.88
Market capitalisation (£m) 95,086.85 Gross gearing (%) 76.85
Shares in issue (m) 1,311.90 Debt ratio 68.34
P/E ratio 42.64 Debt-to-equity ratio 0.65
Total dividends per share (p) 215.20 Assets / equity ratio 4.32
Dividend yield (%) 3.02 Price to book value 6.77
Dividend cover 0.78 ROCE (%) 4.49
Earning per share (p) 170.00 EPS growth (%) -28.27
52-week high / low (p) 7,646.00 / 5,312.00 DPS growth (%) 6.27

Results at a glance

Date Type Turnover (£m) Profit (£m) Basic EPS Currency
31 Dec 2018 Full Year 22,090 2,050 170.00 USD
31 Dec 2017 Full Year 22,465 2,868 237.00 USD
31 Dec 2016 Full Year 23,002 3,406 277.00 USD

Dividend history

Period Ex-date Pay-date Net dividend Currency Total for year
H1 Dividend 08 Aug 2019 09 Sep 2019 71.90 GBX 0.00
H2 Dividend 28 Feb 2019 27 Mar 2019 146.80 GBX 215.20
H1 Dividend 09 Aug 2018 10 Sep 2018 68.40 GBX 0.00
H2 Dividend 15 Feb 2018 19 Mar 2018 133.60 GBX 202.50
H1 Dividend 10 Aug 2017 11 Sep 2017 68.90 GBX 0.00
H2 Dividend 16 Feb 2017 20 Mar 2017 150.20 GBX 218.90
H1 Dividend 11 Aug 2016 12 Sep 2016 68.70 GBX 0.00
H2 Dividend 18 Feb 2016 21 Mar 2016 131.00 GBX 188.50
H1 Dividend 13 Aug 2015 14 Sep 2015 57.50 GBX 0.00
H2 Dividend 19 Feb 2015 23 Mar 2015 125.00 GBX 178.10

Contact details

Company name AstraZeneca
Address 15 Stanhope Gate, London W1K 1LN.
Telephone +44 (0)20 7304 5000
Website http://www.astrazeneca.com/

Advisors

Company's broker Morgan Stanley Securities
Company's joint broker n/a
NOMAD n/a
Registrar Equiniti
Auditors KPMG Audit
Solicitors n/a

Directors

Appointed Director Position
01 Oct 2012 Pascal Claude Roland Soriot Chief Executive Officer
01 Nov 2013 Marc Pierre Jean Dunoyer Chief Financial Officer
26 Apr 2012 Leif Valdemar Johansson Non-Executive Chairman
01 Oct 2017 Sherilyn Dawn McCoy Non-Executive Director
01 Jan 2019 Tony Shu Kam Mok Non-Executive Director
01 Jun 2017 Prof Sabera Nazneen Rahman Non-Executive Director
06 Apr 1999 Marcus Wallenberg Non-Executive Director
01 Sep 2019 Michel Roger Demaré Non-Executive Director
01 Dec 2017 Deborah DiSanzo Non-Executive Director
26 Apr 2012 Graham Andrew Chipchase Non-Executive Director
27 Apr 2017 Philip Arthur John Broadley Non-Executive Director
26 Apr 2012 Prof Geneviève Bernadette Berger Non-Executive Director

Company financials

Assets (£m) 2018 2017 2016
Reporting date 31 Dec 2018 31 Dec 2017 31 Dec 2016
Tangible assets 7,421 7,615 6,848
Intangible asssets and goodwill 33,666 38,013 39,244
Investments and other non-current assets 3,973 4,576 3,172
Total non-current assets 45,060 50,204 49,264
Inventory / work in progress 2,890 3,035 2,334
Trade and other receivables 5,574 5,009 4,573
Cash and equivalents 4,831 3,324 5,018
Other current assets and asset held for resale 2,296 1,782 1,337
Total of all assets 60,651 63,354 62,526
Liabilities (£m) 2018 2017 2016
Short term liabilities 16,292 16,383 15,256
Long term liabilities 30,315 30,329 30,601
Other liabilites / pension etc 0 0 0
Total of all liabilities 46,607 46,712 45,857
Net assets (£m) 2018 2017 2016
Net assets 14,044 16,642 16,669
Equity (£m) 2018 2017 2016
Share capital 317 317 316
Minority interests 1,576 1,682 1,815
Retained earnings 5,683 8,221 8,140
Share premium account 4,427 4,393 4,351
Other equity 2,041 2,029 2,047
Total equity 14,044 16,642 16,669
Cash Flow (£m) 2018 2017 2016
Cash from operating activities 2,618 3,578 4,145
Cashflow before financing 3,581 1,250 176
Increase / decrease in Cash 1,537 -1,686 -1,148
Income (£m) 2018 2017 2016
Turnover 22,090 22,465 23,002
Cost of sales 4,936 4,318 4,126
Gross profit 17,154 18,147 18,876
Operating profit 3,387 3,677 4,902
Pre-tax profit 1,993 2,227 3,552
Profit / loss for the year 2,050 2,868 3,406